Showing 2571-2580 of 5621 results for "".
- Pharma Company Exercises Rights for Exclusive Use of Everads Drug Delivery Technology in Specific Retinal Targetshttps://modernod.com/news/pharma-company-exercises-rights-for-exclusive-use-of-everads-drug-delivery-technology-in-specific-retinal-targets/2478193/Everads Therapy has granted a pharmaceutical company a time-limited exclusivity for utilizing Everads’ suprachoroidal delivery technology for the development of specific ocular targets. In exchange for exclusivity of these specific ocular targets, Everads will receive a milestone payment. E
- Regeneron Boosts Production Capacity for COVID-19 Antibody Cocktail Via Deal With Rochehttps://modernod.com/news/regeneron-boosts-production-capacity-for-covid-19-antibody-cocktail-via-deal-with-roche/2478176/Regeneron Pharmaceuticals said that the overall capacity to produce REGN-COV2, a two-antibody cocktail against COVID-19, will increase by at least 3.5 times under a development and manufacturing collaboration with Roche. As part of the deal, Regeneron will market REGN-COV2 in the US, with Roche r
- Sanofi Enters $3.7-Billion Deal to Buy Principia Biopharmahttps://modernod.com/news/sanofi-enters-3-7-billion-deal-to-buy-principia-biopharma/2478166/Sanofi announced Monday a definitive agreement to acquire all of Principia Biopharma’s outstanding stock for $100 per share in cash, representing an equity value of around $3.7 billion, boosting the French drugmaker’s core research areas of autoimmune and allergic diseases. The deal,
- Diagnostic Market Sees New Demand Due to Effects of COVID-19https://modernod.com/news/diagnostic-market-sees-new-demand-due-to-effects-of-covid-19/2478150/Increasing demand for telehealth and mobile applications due to the COVID-19 pandemic has led manufacturers to scramble to add functionality and accessibility to existing devices and protection apparatuses or create new devices, according to a Market Scope report. Regulatory bodies and re
- Ocugen Receives Fourth FDA Orphan Drug Designation for Gene Therapy for the Treatment of Another Inherited Retinal Diseasehttps://modernod.com/news/ocugen-receives-fourth-fda-orphan-drug-designation-for-gene-therapy-for-the-treatment-of-another-inherited-retinal-disease/2478149/Ocugen announced the FDA granted the fourth Orphan Drug Designation (ODD) for OCU400 in the treatment of PDE6B gene mutation-associated retinal diseases. Retinitis Pigmentosa (RP) caused by PDE6B mutation is an inherited retinal dystrophy that leads to blindness by midlife and
- Eyenovia and Arctic Vision Announce License Agreement to Develop and Commercialize Products in Greater China and South Koreahttps://modernod.com/news/eyenovia-and-arctic-vision-announce-license-agreement-to-develop-and-commercialize-products-in-greater-china-and-south-korea/2478143/Eyenovia and Arctic Vision announced that they have entered into an exclusive license agreement for Arctic Vision to develop and commercialize MicroPine for the treatment of progressive myopia and MicroLine for the treatment of presbyopia in Greater China (mainland China, Hong Kong, Macau and Tai
- AstraZeneca Takes COVID-19 Vaccine to China With BioKangtai Deal for 200M-Dose Capacity by 2021https://modernod.com/news/astrazeneca-takes-covid-19-vaccine-to-china-with-biokangtai-deal-for-200m-dose-capacity-by-2021/2478134/Last week China was a notable missing element in AstraZeneca’s COVID-19 vaccine strategy, despite being the drugmaker’s second-largest market. That has changed, according to a FiercePharma
- New Evidence Suggests Young Children Spread COVID-19 More Efficiently Than Adultshttps://modernod.com/news/new-evidence-suggests-young-children-spread-covid-19-more-efficiently-than-adults/2478128/Two new studies, though from different parts of the world, have arrived at the same conclusion: that young children not only transmit SARS-CoV-2 efficiently, but may be major drivers of the pandemic as well, according to a Forbes
- EyePoint Pharmaceuticals and ImprimisRx Announce U.S. Commercial Alliance for Dexycuhttps://modernod.com/news/eyepoint-pharmaceuticals-and-imprimisrx-announce-u-s-commercial-alliance-for-dexycu/2478119/EyePoint Pharmaceuticals and ImprimisRx announced the signing of a commercial alliance for the joint promotion of Dexycu (dexamethasone intraocular suspension) 9% for the treatment of postoperative inflammation following ocular surgery in the United States.
- Sanofi, GSK Gain $2.1 Billion From US Government for Development, Supply of COVID-19 Vaccinehttps://modernod.com/news/sanofi-gsk-gain-2-1-billion-from-us-government-for-development-supply-of-covid-19-vaccine/2478107/Sanofi and GlaxoSmithKline announced that the US government will provide more than $2.1 billion to support further development, manufacturing and delivery of initial doses of the companies’ adjuvanted vaccine against COVID-19. The vaccine candidate is based on Sanofi’s recombinant pro